摘要
目的:探讨血管性血友病因子(VWF)、D-二聚体(D-D)、纤维蛋白降解产物(FDP)、抗凝血酶-Ⅲ(AT-Ⅲ)检测诊断多发性骨髓瘤的临床价值。方法:选取2019年10月—2020年10月佛山复星禅诚医院收治的初诊多发性骨髓瘤患者78例为观察组,使用国际分期系统划分为Ⅰ期(n=18)、Ⅱ期(n=24)及Ⅲ期(n=36),经临床治疗后分为未缓解组(n=28)与缓解组(n=50);选取同期体检健康人78例为对照组。比较各组VWF、D-D、FDP及AT-Ⅲ水平。结果:观察组VWF、D-D及FDP水平高于对照组,AT-Ⅲ水平低于对照组,差异有统计学意义(P<0.05);缓解组VWF、D-D及FDP水平低于未缓解组,AT-Ⅲ水平高于未缓解组,差异有统计学意义(P<0.05);Ⅰ期患者VWF、D-D及FDP水平低于Ⅱ期患者低于Ⅲ期患者,AT-Ⅲ水平高于Ⅱ期患者高于Ⅲ期患者,差异有统计学意义(P<0.05)。结论:多发性骨髓瘤患者多表现为纤溶与凝血指标异常,对VWF、D-D、FDP及AT-Ⅲ等指标检测可准确有效判断疾病分期,为临床治疗提供重要依据。
Objective:To investigate the clinical value of von willebrand factor(VWF),D-dimer(D-D),fibrin degradation product(FDP)and antithrombine-Ⅲ(AT-Ⅲ)in diagnosis of multiple myeloma.Methods:Seventy-eight newly diagnosed multiple myeloma patients admitted to Fosun Chancheng Hospital from October 2019 to October 2020 were selected as the observation group.They were divided into stageⅠ(n=18),stage II(n=24)and stageⅢ(n=36)using the international staging system.After clinical treatment,they were divided into non-remission group(n=28)and remission group(n=50).Seventy-eight healthy subjects in the same period were selected as control group.The levels of VWF,D-D,FDP and AT-Ⅲwere compared.Results:The levels of VWF,D-D and FDP in the observation group were higher than those in the control group,while the levels of AT-Ⅲwere lower than those in the control group,and the difference was statistically significant(P<0.05).The levels of VWF,D-D and FDP in remission group were lower than those in non-remission group,while AT-Ⅲlevel was higher than that in non-remission group,with statistical significance(P<0.05).The level of VWF,D-D and FDP in stage I patients was lower than that in stage n patients than that in stageⅢpatients,and the level of AT-Ⅲwas higher than that in stageⅡpatients than that in stageⅢpatients,the difference was statistically significant(P<0.05).Conclusion:The abnormal fibrinolysis and coagulation indexes in multiple myeloma patients can accurately and effectively determine the stage of the disease by the detection of VWF,D-D,FDP,AT-Ⅲand other indexes,providing an important basis for clinical treatment.
作者
陈仲桓
冉江帆
劳武斌
叶缪青
刘锋
Chen Zhong-huan;Ran Jiang-fan;Lao Wu-bin;Ye Miao-qing;Liu Feng(Department of Clinical Laboratory,Fosun Chancheng Hospital,Foshan 528000,Guangdong Province,China)
出处
《中外医药研究》
2022年第18期129-131,共3页
JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH
